The Under-Performance of Facebook

The shellacking of Facebook (FB) for over a week of scandal-ridden headlines has created that rare beast in the jungle of tech stocks: a “value” play. Facebook has a trailing P/E of 29.6 and a forward P/E of 17.9. Quarterly earnings growth is running at 19.6% year-over-year. According to briefing.com year-over-year revenue growth has run … Read more

Financially Vulnerable: A Critical Test for Financial Stocks

This week, I blithely accumulated call options on Goldman Sachs (GS) ahead of and after the Federal Reserve’s latest declaration on monetary policy. I assumed that the Fed’s calming influence would remind market participants that the economy is fine and the prospects are good. Under that scenario financial stocks would do well as long-term interest … Read more

Above the 40 (March 19, 2018) – A Sharp Edge Cuts A Churning Stock Market

AT40 = 42.9% of stocks are trading above their respective 40-day moving averages (DMAs) (traded as low as 37.6%) AT200 = 47.9% of stocks are trading above their respective 200DMAs VIX = 19.0 (traded as high as 21.9) Short-term Trading Call: neutral Commentary In my last Above the 40 post, I described how the stock … Read more

Above the 40 (March 16, 2018) – The Stock Market Stumbles Back to A Sharp Edge

AT40 = 49.0% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 50.1% of stocks are trading above their respective 200DMAs VIX = 15.8 Short-term Trading Call: bullish Commentary Another proclamation on monetary policy from the Federal Reserve is just 3 trading days away. Hanging in the balance is the S&P … Read more

Lessons from the DexCom Breakout

Five months ago, I made the case for bottom-fishing in DexCom (DXCM) following the news of competitor’s Abbott (ABT) product approval. The trade was looking shaky a few weeks later when the stock made a minor new closing low from that price collapse. November earnings produced the catalyst to confirm the bottom, and the stock … Read more